Article
Geriatrics & Gerontology
Maria Cespon-Fernandez, Sergio Raposeiras-Roubin, Emad Abu-Assi, Maria Melendo-Viu, Enrique Garcia-Campo, Andres Iniguez-Romo
Summary: The study found that treatment with ACEi or ARB did not improve outcomes in terms of survival and cardiovascular events in older patients with AF. More randomized clinical trials specifically in the older AF patient population are needed to address this issue conclusively.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Article
Medicine, General & Internal
Seok Hui Kang, Bo Yeon Kim, Eun Jung Son, Gui Ok Kim, Jun Young Do
Summary: This study aimed to evaluate patient survival with the use of renin-angiotensin system blockers (RASBs) in maintenance hemodialysis (HD) patients, and found that the use of RASBs was associated with higher patient survival rates.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Wei Xu, Yan-min Yang, Jun Zhu, Shuang Wu, Juan Wang, Han Zhang, Xing-hui Shao
Summary: This study found that ACEI/ARB therapy was significantly associated with a reduced risk of all-cause death, cardiovascular death, and MAEs in ED patients with AF and hypertension.
BMC CARDIOVASCULAR DISORDERS
(2022)
Review
Pharmacology & Pharmacy
Persoulla A. Nicolaou
Summary: Sex-related differences in clinical manifestations, risk factors, and treatment drug use in patients with heart failure are significant, particularly in the regulation of the renin-angiotensin-aldosterone system (RAAS). While current evidence suggests potential differences in the efficacy of RAAS drugs between men and women, further research is needed to determine the optimal treatment strategies for both genders.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Urology & Nephrology
Kengo Azushima, Jean -Paul Kovalik, Takahiro Yamaji, Jianhong Ching, Tze Wei Chng, Jing Guo, Jian-Jun Liu, Mien Nguyen, Rashidah Binte Sakban, Simi E. George, Puay Hoon Tan, Su Chi Lim, Susan B. Gurley, Thomas M. Coffman
Summary: This study found that in a mouse model of diabetic nephropathy, there were elevated lactate levels and impaired energy metabolism in the kidneys. Treatment with an angiotensin-receptor blocker (ARB) improved these abnormalities. Increased expression of lactate dehydrogenase isoforms, specifically LdhA in the proximal tubule, was also observed. Urinary lactate levels were found to be predictive of clinical outcomes in diabetic patients with kidney disease.
KIDNEY INTERNATIONAL
(2023)
Article
Cardiac & Cardiovascular Systems
Zhijie Liu, Ning Bian, Shaorong Wu, Yantao Cao, Yiting Su, Wenying Li, Hairui Li, Xianwu Lan, Can Jiang, Yiming Fan, Jun Guo, Dongdong Chen
Summary: This study aimed to investigate the effects of ACEI/ARB and CCB on the risk of NOAF for hypertensive patients with PPI. The results showed that ACEI/ARB were associated with a lower risk of NOAF compared to CCB, and they also had better improvement in left atrial remodelling.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Jing Lin, Liu He, Qing Qiao, Xin Du, Chang-Sheng Ma, Jian-Zeng Dong
Summary: The study on the effect of renin-angiotensin system inhibitors in patients with heart failure and atrial fibrillation found that RASI use was not associated with better outcomes in this specific subset, while beta-blocker use was linked to significantly lower all-cause mortality in the same population.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Sam Siljee, Bridget Milne, Helen D. Brasch, Nicholas Bockett, Josie Patel, Paul F. Davis, Andrew Kennedy-Smith, Tinte Itinteang, Swee T. Tan
Summary: This study demonstrated the expression of PRR, ACE2, and AT(2)R by the CSCs within RCCC. Further studies may lead to novel therapeutic targeting of CSCs by manipulation of the RAS in the treatment of this aggressive cancer.
Review
Neurosciences
Naif H. Ali, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Rabab S. Hamad, Athanasios Alexiou, Marios Papadakis, Hebatallah M. Saad, Gaber El-Saber Batiha
Summary: This article discusses the pathophysiology of depression and the role of the brain renin-angiotensin system (RAS) in it. It is found that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be effective in the treatment of depression. By regulating serotonin, brain-derived neurotrophic factor, mitochondrial dysfunction, oxidative stress, and neuroinflammation, these drugs can ameliorate the pathophysiology of depression.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Cardiac & Cardiovascular Systems
Chan Soon Park, Han-Mo Yang, Jeehoon Kang, Jung-Kyu Han, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Ki-Bae Seung, Kwang Soo Cha, In-Whan Seong, Seung-Woon Rha, Myung Ho Jeong, Hyo-Soo Kim, KAMIR-NIH Registry
Summary: The use of Renin-angiotensin-system inhibitors (RASi) medication at 1-year follow-up did not show any improvement in 2-year all-cause mortality or cardiac mortality for patients after acute myocardial infarction (MI). This study provides valuable information for tailored medication strategies after acute MI.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Sheng Wei Lo, Jonathan P. P. Segal, John S. S. Lubel, Mayur Garg
Summary: This review summarizes the current understanding of the physiological mechanism of the renin-angiotensin system in inflammatory bowel disease and explores its potential therapeutic implications.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2022)
Article
Multidisciplinary Sciences
Keita Watanabe, Yasutoshi Nagata, Giichi Nitta, Shinichiro Okata, Masashi Nagase, Ryoichi Miyazaki, Sho Nagamine, Masakazu Kaneko, Tetsumin Lee, Toshihiro Nozato, Takashi Ashikaga, Masahiko Goya, Tetsuo Sasano
Summary: This study found that patients with a longer sinus node recovery time (SNRT) had a higher recurrence rate of atrial fibrillation after the first ablation and a higher inducibility of non-pulmonary vein triggers. Therefore, measuring SNRT may be useful for stratifying patients with persistent AF.
Review
Peripheral Vascular Disease
Yasushi Matsuzawa, Kazuo Kimura, Hisao Ogawa, Kouichi Tamura
Summary: This article summarizes the potential effects of RAS inhibitors and their impact on COVID-19, indicating that further research is needed to confirm their role.
HYPERTENSION RESEARCH
(2022)
Review
Urology & Nephrology
Jordana B. Cohen, Andrew M. South, Hossam A. Shaltout, Matthew R. Sinclair, Matthew A. Sparks
Summary: During the early months of the COVID-19 pandemic, controversy arose over the hypothesis that pharmacologic inhibitors of the renin-angiotensin system (RAS) may exacerbate COVID-19 severity. While some evidence suggests potential protective effects of ACE2 and RAS blockade on acute lung injury, there are risks associated with discontinuing these medications. Further research and examination of this topic are warranted to improve understanding of these complex relationships.
CLINICAL KIDNEY JOURNAL
(2021)
Review
Cell Biology
Filipa Gouveia, Antoni Camins, Miren Ettcheto, Joana Bicker, Amilcar Falcao, M. Teresa Cruz, Ana Fortuna
Summary: Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by Tau hyperphosphorylation and A beta deposits. Recent scientific evidence suggests that age-related vascular alterations and cardiovascular risk factors play a role in the development of AD. Drugs targeting the Renin Angiotensin System (RAS) have the potential to delay AD development due to their effects on brain RAS. The ACE 1/Ang II/AT1R axis in AD is believed to have detrimental effects, while the alternative axis ACE 1/Ang II/AT2R; ACE 2/Ang (1 7)/MasR; Ang IV/AT4R (IRAP) seems to have beneficial effects on memory and cognition. Retrospective studies and pre-clinical studies support the therapeutic potential of RAS drugs for AD.
AGEING RESEARCH REVIEWS
(2022)